Sarepta Therapeutics, Inc. (SRPT)

Sarepta Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Revenue	1,403	1,243	933.01	701.89	540.1	380.83
Revenue Growth (YoY)	43.83%	33.26%	32.93%	29.96%	41.82%	26.51%
Cost of Revenue	165.89	150.34	139.99	97.05	63.38	56.59
Gross Profit	1,237	1,093	793.02	604.84	476.72	324.25
Selling, General & Admin	498.16	481.87	451.42	282.66	317.88	284.81
Research & Development	832.1	877.39	877.09	771.18	722.34	560.91
Other Operating Expenses	1.98	1.56	0.71	10.71	0.66	184.09
Operating Expenses	1,332	1,361	1,329	1,065	1,041	1,030
Operating Income	-94.83	-267.82	-536.2	-459.71	-564.16	-705.56
Other Expense / Income	-128.89	252.27	153.76	-40.76	-11.1	8.32
Pretax Income	34.06	-520.1	-689.96	-418.95	-553.07	-713.88
Income Tax	17.16	15.88	13.53	-0.17	1.06	1.2
Net Income	16.9	-535.98	-703.49	-418.78	-554.13	-715.08
Shares Outstanding (Basic)	94	92	88	81	78	74
Shares Outstanding (Diluted)	99	92	88	81	78	74
Shares Change	12.39%	5.53%	7.75%	4.24%	5.90%	11.12%
EPS (Basic)	0.41	-5.80	-8.03	-5.15	-7.11	-9.71
EPS (Diluted)	0.40	-5.80	-8.03	-5.15	-7.11	-9.71
Free Cash Flow	-632.74	-577.1	-356.17	-481.66	25.26	-516.09
Free Cash Flow Per Share	-6.73	-6.25	-4.07	-5.93	0.32	-7.01
Gross Margin	88.18%	87.91%	85.00%	86.17%	88.26%	85.14%
Operating Margin	-6.76%	-21.54%	-57.47%	-65.50%	-104.46%	-185.27%
Profit Margin	1.20%	-43.11%	-75.40%	-59.66%	-102.60%	-187.77%
Free Cash Flow Margin	-45.09%	-46.42%	-38.17%	-68.62%	4.68%	-135.52%
Effective Tax Rate	50.39%	-	-	-	-	-
EBITDA	91.13	-461.21	-635.36	-369.61	-513.33	-683.33
EBITDA Margin	6.49%	-37.09%	-68.10%	-52.66%	-95.04%	-179.43%
Depreciation & Amortization	57.07	58.89	54.6	49.34	39.74	30.55
EBIT	34.06	-520.1	-689.96	-418.95	-553.07	-713.88
EBIT Margin	2.43%	-41.83%	-73.95%	-59.69%	-102.40%	-187.45%

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).